Bristol Myers: heavy quarterly loss on charges
The pharmaceutical company explains this heavy loss by the non-recurring net impact of acquired IPRD charges and license revenues from recently concluded transactions, an impact amounting to $6.30 per share.
These charges have led the Group to drastically update its target range for adjusted EPS for the current year: it now expects it to be between $0.40 and $0.70, instead of the previous estimates of $7.10 to $7.40.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction